CEO John Womelsdorf

About Aimm Therapeutics
CEO John Womelsdorf

Management

CEO John Womelsdorf, PhD, MBA

Prior to joining AIMM, John Womelsdorf performed the role lead negotiator at both Roche and Johnson & Johnson. When appointed to the Board of Tibotec Therapeutics, a member of the J&J family of companies, Womelsdorf helped to transition the business into a commercial entity with the successful launch of PrezistaTM (darunivir) for the treatment of HIV. More recently, he served as the vice president of business development at both Cyclacel Pharmaceuticals and Optimer Pharmaceuticals (acquired by Cubist in 2013).